We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostica Stago Acquires Dutch Thrombin Generation Company

By LabMedica International staff writers
Posted on 20 Oct 2010
Print article
Diagnostica Stago, Inc. (DSI; Parsippany, NJ, USA), finalized the acquisition of Thrombinoscope, BV (Maastricht, The Netherlands). Originally developed at Maastricht University, Thrombinoscope, researches, develops, and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram (CAT) system. The CAT system is available for research-only use.

"The development potential of this new TG approach in hemostasis using the CAT system is very promising," noted Stephane Zamia, Ph.D., and CEO of DSI. "The addition of this approach to Stago's portfolio will allow our customers to measure TG in real-time and in larger, scalable studies."

Operations and research at the company will remain independent within the Stago Group, and will report directly to the company's scientific and clinical department. The Stago Group believes that by remaining independently controlled, this start-up company will continue promising creativity leading to product development, citing their recent acquisition of BioCytex (Marseille, France), a company specializing in standardized kits for flow cytometric analysis of blood cells.

TG is a universal test capable of assessing a patient's global hemostatic balance in the instance of hemorrhage or thrombosis. Few methods before this had allowed for TG standardization and calibration. Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thereby giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies, and contract research organizations.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France (Asnières sur Seine, France), a developer and manufacturer of Hemostasis products.

Related Links:

Diagnostica Stago
Thrombinoscope




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.